Nervgen Pharma Corp Stock Last Dividend Paid
| NGENF Stock | USD 1.87 0.05 2.60% |
NervGen Pharma Corp fundamentals help investors to digest information that contributes to NervGen Pharma's financial success or failures. It also enables traders to predict the movement of NervGen OTC Stock. The fundamental analysis module provides a way to measure NervGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NervGen Pharma otc stock.
NervGen |
NervGen Pharma Corp OTC Stock Last Dividend Paid Analysis
NervGen Pharma's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, NervGen Pharma Corp has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
NervGen Last Dividend Paid Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NervGen Pharma's direct or indirect competition against its Last Dividend Paid to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of NervGen Pharma could also be used in its relative valuation, which is a method of valuing NervGen Pharma by comparing valuation metrics of similar companies.NervGen Pharma is currently under evaluation in last dividend paid category among its peers.
NervGen Fundamentals
| Return On Equity | -1.42 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 48.78 M | |||
| Shares Outstanding | 58.68 M | |||
| Shares Owned By Insiders | 25.27 % | |||
| Price To Book | 5.13 X | |||
| EBITDA | (11.33 M) | |||
| Net Income | (12.73 M) | |||
| Cash And Equivalents | 11.65 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 324.69 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 4.25 X | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (8.27 M) | |||
| Earnings Per Share | (0.28) X | |||
| Beta | 1.7 | |||
| Market Capitalization | 87.43 M | |||
| Total Asset | 17.9 M | |||
| Net Asset | 17.9 M |
About NervGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in NervGen OTC Stock
NervGen Pharma financial ratios help investors to determine whether NervGen OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NervGen with respect to the benefits of owning NervGen Pharma security.